NEW YORK (GenomeWeb News) — Mirus Bio yesterday said it has signed a two-year, “multi-million dollar” deal with Pfizer to target and suppress the expression of certain genes.
Under the deal, Mirus said it will study methods for optimizing gene silencing methods in animals.
Mirus said the agreement will help it speed development of delivery methods for its RNAi technology.
Mirus markets DNA and siRNA transfection and labeling products, and is developing therapeutic products using its Pathway IV delivery platform.
Financial terms of the agreement were not released.